CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, presented noteworthy new data at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago on April 28. The study showed how engineered cells derived from stem cells could transform the treatment of ovarian cancer. The data revealed that these engineered cells, which release powerful immune-boosting cytokines, not only shrink tumors but also help the body's immune system to attack the cancer more effectively. "We've taken cells that normally help repair tissues in the body and repr

CAMBRIDGE, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that new data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The study explored the technology behind Ernexa's lead cell therapy product, ERNA-101, which uses specially engineered cells to deliver treatment directly to ovarian tumors. By secreting immune-stimulating cytokines, this cell therapy treatment aims to reshape the tumor microenvironment and enhance anti-tumor immune responses, fighting off the cancer. The study was led by M

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has entered into a securities purchase agreement with accredited investors for the private placement of approximately 69.3 million shares of common stock (or pre-funded warrants to purchase shares of common stock), at a purchase price of $0.1046 per share for an aggregate purchase price of approximately $7,250,000, assuming the Company receives stockholder approval. "These are very exciting times at Ernexa, as we advance therapeutic innovation in cell therapy for the benefit of pati

Ernexa Therapeutics embarks on new strategic direction, shifting the company's focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company's unwavering commitment to patient impact,"Breaking Through Defenses, Delivering Hope" CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics, a leader in cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the company's new name: Ernexa TherapeuticsSM (NASDAQ:ERNA). The new name reflects the company's laser-focused mission and ambitious vision. "Eterna Therapeutics began as a pioneer developing an innovative and differentiated cell th

CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (NASDAQ:ERNA), developing innovative cell therapies for the treatment of advanced solid tumors and autoimmune diseases, today announced a successful inaugural meeting of its newly formed Scientific Advisory Board. The meeting brought together leading experts in cell therapy to evaluate preclinical advances, address key scientific questions, refine the company's research and development priorities, and discuss the roadmap to human clinical trials. The board consists of top leaders in the field, including: Michael Andreeff, MD, PhD, Professor in the Departments of Leukemia and Stem Cell Transplantation at The Universit

CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (NASDAQ:ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the addition of Jerome Zeldis, M.D., Ph.D., and Blythe Sather, Ph.D., to the company's scientific advisory board. "We are fortunate to welcome Dr. Zeldis and Dr. Sather," said Sanjeev Luther, President & CEO of Eterna Therapeutics. "Their extensive experience in developing transformative, high-profile cell therapies for solid tumors has been pivotal in advancing innovative treatments for patients. Their deep expertise will be invaluable as we continue to advance our cell therapies." Dr. Zeldis brings decades

CAMBRIDGE, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (NASDAQ:ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced positive results from a preclinical study on the company's lead cell therapy product, ERNA-101, which is designed to activate and regulate the immune system's response to recognize and attack ovarian cancer cells. This successful proof-of-concept study demonstrated massive T cell infiltration after only one dose of ERNA-101, reduced tumor burden, and extended survival in mice with ovarian cancer. "We are thrilled by the positive results, which represent a significant milestone for ERNA-101 and Eterna Therapeutics," s

CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (NASDAQ:ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the appointment of Elena Ratner, M.D., M.B.A, to the Board of Directors. Dr. Ratner will spearhead the strategic direction of Eterna's efforts to combat ovarian cancer, leveraging her extensive expertise in obstetrics, gynecology, and reproductive sciences. Under her leadership, the company aims to accelerate advancements in innovative therapies targeting these high-priority areas in women's health. This direction is bolstered by Eterna's recent collaboration with MD Anderson Cancer Center. Announced last month, the p

CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics (NASDAQ:ERNA) today announced it will investigate the ability of its lead iMSC-based cell therapy (ERNA-101) to induce and modulate antitumor immunity in ovarian cancer and breast cancer models through a sponsored research agreement with The University of Texas MD Anderson Cancer Center. ERNA-101 is Eterna's proprietary allogenic IL-7 and IL-15-secreting induced pluripotent stem cell (iPSC) derived mesenchymal stem cells (iMSC) product candidate. Researchers will investigate immunomodulatory effects of ERNA-101 in vitro and antitumor immunity of ERNA-101 in ovarian cancer and breast cancer models in vivo. Based on res

CAMBRIDGE, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics, Inc. (NASDAQ:ERNA), a leader in cell therapies, today announced that its Board of Directors has authorized a stock repurchase program of up to $1 million of the company's outstanding common stock. This program reflects the Board's confidence in the company's long-term strategy and commitment to enhancing shareholder value. Under the stock repurchase program, the repurchases may be made by the Company from time to time through open market transactions, privately negotiated transactions, or other means in accordance with applicable securities laws. The timing and amount of repurchases will be determined by the comp

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) --  Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution of a securities purchase agreement with accredited investors for the sale of approximately $9.2 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase an aggregate of 9,579,014 shares of common stock in a private placement transaction that was priced at-the-market under Nasdaq rules. The Company expects to hold an initial closing at which it exp

CAMBRIDGE, MASS., July 18, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution and closing of the sale of approximately $8.7 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase common stock in a private placement transaction that closed on July 14, 2023 and was priced at-the-market under Nasdaq rules. The notes, which were issued at par, bear interest at a rate of 6.0% per year, payable quarterly, and mature in July 2028

Acquisition includes Exacis' entire pipeline of engineered cell therapy programs for hematologic and solid tumors CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics ("Exacis"). The acquisition complements Eterna's core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors and provides Eterna with an exclusive g

– Executed income generating license agreement with Lineage Cell Therapeutics to develop gene-edited induced pluripotent stem cell (iPSC)-derived therapies for multiple neurology indications – Entered into a sublease agreement with Bristol Myers Squibb to occupy 45,000 sq. ft. of lab and office space at Cambridge Crossing development in Cambridge, Massachusetts – Appointed Matt Angel, Ph.D. as Chief Executive Officer and President CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicine

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

EFFECT - Ernexa Therapeutics Inc. (0000748592) (Filer)

424B3 - Ernexa Therapeutics Inc. (0000748592) (Filer)

S-3 - Ernexa Therapeutics Inc. (0000748592) (Filer)

DEF 14A - Ernexa Therapeutics Inc. (0000748592) (Filer)

PRE 14A - Eterna Therapeutics Inc. (0000748592) (Filer)

8-K - Eterna Therapeutics Inc. (0000748592) (Filer)

8-K - Eterna Therapeutics Inc. (0000748592) (Filer)

8-K - Eterna Therapeutics Inc. (0000748592) (Filer)

10-K - Eterna Therapeutics Inc. (0000748592) (Filer)

8-K - Eterna Therapeutics Inc. (0000748592) (Filer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

3 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (NASDAQ:ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the appointment of Elena Ratner, M.D., M.B.A, to the Board of Directors. Dr. Ratner will spearhead the strategic direction of Eterna's efforts to combat ovarian cancer, leveraging her extensive expertise in obstetrics, gynecology, and reproductive sciences. Under her leadership, the company aims to accelerate advancements in innovative therapies targeting these high-priority areas in women's health. This direction is bolstered by Eterna's recent collaboration with MD Anderson Cancer Center. Announced last month, the p

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a preclinical-stage biopharmaceutical company, committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announces the appointment of Mahendra Rao, PhD, to its scientific advisory board. "We're honored to have Dr. Mahendra Rao join our Scientific Advisory Board," said Sanjeev Luther, President and CEO of Eterna. "His deep scientific expertise in regenerative medicine and cell engineering will be invaluable to our company in its upcoming phases of scientific and clinical development as we strive to brin

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Peter Cicala, JD, to its Board of Directors. "Peter Cicala has deep experience in the biotechnology and pharmaceutical industry, from start-ups to big pharma, and from bench to commercialization," said Sanjeev Luther, President and CEO of Eterna. "We are very pleased to have him join our Board to support value creation through the development of next-generation therapies using mRNA cell engineerin

CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, has appointed Sanjeev Luther as President and Chief Executive Officer and a member of the company's Board of Directors, effective January 1, 2024. Mr. Luther will replace Matt Angel, Ph.D., the current President and Chief Executive Officer. James Bristol, Ph.D., Chairman of Eterna's Board of Directors, said, "We are excited to have Sanjeev take on the role of President and CEO of Eterna as we continue our work to support the deve

CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of James Bristol, Ph.D., to its Board of Directors. "Dr. Bristol is a seasoned biopharmaceutical executive who has excelled as a corporate partner, board member, and strategic and technical advisor within our industry," said Matt Angel, Ph.D., Chief Executive Officer and President of Eterna. "We are thrilled to have him join our Board as we continue our mission of supporting the development of next-g

CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Dorothy Clarke to its Board of Directors. "We are delighted to welcome Dorothy to our Board," said Matt Angel, Ph.D., Chief Executive Officer and President of Eterna. "Dorothy's extensive regulatory and legal expertise and experience as a Fortune 100 executive in the biopharmaceutical and healthcare sector will be invaluable as we continue to execute on our business and partnering strategies to

CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Brant Binder and Richard Wagner, Ph.D. to its Board of Directors. Concurrently, Charles Cherington and Nicholas Singer have stepped down from the Board. "We are delighted to welcome Brant and Richard to our Board. Both bring a wealth of industry expertise, including founding and leading biotechnology companies with a proven history of delivering value for their stakeholders," said Matt Angel, Ph.D

Renowned scientist and serial entrepreneur Jeff Karp, Ph.D., brings deep research experience and industry knowledge that will help guide Eterna as it advances its mRNA cell engineering platform CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Jeff Karp, Ph.D. to Eterna's Scientific Advisory Board. Matt Angel, Ph.D., Chief Executive Officer and President of Eterna, commented, "Jeff is a world-class expert in drug delivery and cell therapeutics